Breathing Trouble: A Glimpse into the World of CRD in Poultry
India ranks second globally in egg production and fifth in poultry meat production. The Indian poultry market, despite being one of the largest globally, remains a developing sector due to its fragmented infrastructure, inconsistent biosecurity standards, and varying degrees of modernization across regions.

A significant portion of poultry production still relies on open housing systems, limited automation, and minimal veterinary oversight, especially among smallholder and backyard farmers. These conditions foster high disease prevalence, as poor sanitation, overcrowding, and lack of structured vaccination programs create ideal environments for the spread of infectious agents like Mycoplasma gallisepticum, E. coli, and coccidia. Consequently, the industry faces substantial economic losses through reduced productivity, higher mortality, increased medication costs, and trade restrictions. Bridging the gap between traditional practices and scientific poultry management is critical for improving flock health and sustaining long-term growth.

One Breath at a Time: Poultry Farmers Battle Chronic Respiratory Disease

Before any effective fight against Chronic Respiratory Disease (CRD) can begin, the poultry industry must first understand the enemy it faces. CRD is not just another seasonal illness—it’s a complex, persistent infection primarily caused by Mycoplasma gallisepticum, capable of silently spreading through flocks and leaving devastating economic consequences in its wake. Its symptoms often mimic those of other respiratory illnesses, making early detection a challenge. Without a clear understanding of its pathogenesis, transmission, and triggers, efforts to control CRD remain reactive and insufficient. Knowledge is the first line of defense—only with education, diagnosis, and structured prevention can farmers hope to break the cycle of recurring outbreaks. The battle against CRD must begin with awareness and be fought with science, vigilance, and unity across the industry.

Unmasking the Culprit: The Hidden Cause of CRD in Poultry

CRD is caused by Mycoplasma gallisepticum (MG), a wall-less bacterium that affects the respiratory tract of poultry. Secondary infections with Escherichia coli, Ornithobacterium rhinotracheale, and viral pathogens (NDV, IBV) often exacerbate disease severity.

Silent Spread: How CRD Continues to Lurk in Poultry Farms
CRD in poultry, caused by Mycoplasma gallisepticum, spreads through both horizontal and vertical transmission. Infected birds release the pathogen via respiratory secretions, contaminating air, water, feed, and equipment. Vertical transmission from breeder hens to chicks via eggs further fuels early infection. Recovered birds often remain silent carriers, shedding the organism under stress. This makes CRD hard to eradicate and highlights the need for strong biosecurity, breeder screening, and flock management to control its spread.

How CRD Takes Hold: Understanding the Disease’s Journey in Poultry
The pathogenesis of Chronic Respiratory Disease (CRD) in poultry begins when birds inhale aerosolized Mycoplasma gallisepticum, the primary causative agent. The pathogen adheres to the ciliated epithelial cells lining the upper respiratory tract, disrupting the mucociliary clearance mechanism. This allows the bacteria to colonize and multiply, triggering a chronic inflammatory response that leads to thick mucus secretion, tracheitis, and air-sacculitis. The damaged respiratory lining also becomes highly susceptible to secondary bacterial infections, particularly from E. coli, compounding respiratory distress and systemic illness.

In commercial poultry, stress factors such as poor ventilation, high stocking density, and concurrent viral infections (like IBV or NDV) can further exacerbate disease progression, resulting in reduced growth rates, poor feed conversion, decreased egg production, and increased mortality.

Signs & Symptoms with Postmortem (PM) Findings
CRD in poultry typically presents with a range of respiratory signs that can vary in severity based on age, immune status, and presence of co-infections. Common clinical signs include coughing, sneezing, nasal discharge, tracheal rales, conjunctivitis, reduced feed intake, stunted growth, and a noticeable drop in egg production in layers. Birds may also exhibit open-mouth breathing and watery eyes. In chronic stages, swelling of infraorbital sinuses and air-sacculitis becomes evident. On postmortem examination, the most consistent findings include thickened, cloudy air sacs (airsacculitis), catarrhal to caseous exudate in the trachea and bronchi, perihepatitis, pericarditis, and fibrinous pneumonia. In cases complicated by secondary infections like E. coli, lesions become more severe, showing a classic “CRD complex.”

Integrated Strategy to Fight CRD
An integrated CRD control strategy combines biosecurity, vaccination, early detection, nutritional support, and precision medication.

Preventive Phase: Reducing the Latent Load
Forlutin 10% (Tiamulin 10%) a high-quality feed additive by Stallen South Asia Pvt. Ltd. serves as the cornerstone for preventive management. Administering it to growers between 7 to 14 weeks of age or just before expected stress periods such as vaccination or peak lay helps reduce the latent load of Mycoplasma. This approach prepares the flock by lowering the pathogen load before the birds reach a vulnerable stage.

Outbreak Management: When Clinical Signs Appear
At the onset of clinical signs indicative of Mycoplasmosis, immediate action is required. Stalmicosin (Tilmicosin Phosphate 250mg) oral solution – a high-quality product manufactured by Stallen South Asia Pvt. Ltd. in its own manufacturing facility to ensure the highest Quality standards, administered via drinking water at 15–20 mg/kg body weight, is highly effective due to its deep lung penetration and prolonged action. This should be continued for 3 to 5 days but not exceeded.

Following the Stalmicosin course, a 24–48hour break should be observed before beginning treatment with Forlutin 80% (Tiamulin 80%) water soluble powder. A dosage of 25–50 mg/kg body weight for another 3 to 5 days helps eliminate residual Mycoplasma and prevents recurrence. Integrating these antimicrobials into a scheduled rotation can significantly reduce disease recurrence and resistance development.

Monitoring and Biosecurity: Supporting the Antimicrobial Strategy
Surveillance using PCR and ELISA tests at regular intervals is vital to detect Mycoplasma presence, especially during and after stress periods. Swab sampling and necropsy examinations for lesions such as air sacculitis or swollen joints provide further evidence. Strict biosecurity—enforcing all-in/all-out practices, staff segregation, and regular disinfection using NADCC, quaternary ammonium compounds, or glutaraldehyde—is essential to support the medical interventions.

References
1. Indian Journal of Veterinary Science & Poultry Health, 2023. Comparative Efficacy of Antibiotics in CRD.
2. Practical Poultry Guide, Vol 18, 2024 – Antimicrobial Resistance Trends in Poultry Pathogens.
4. McOrist et al. (2002) – Tilmicosin pharmacokinetics and tissue distribution in avian models.
5. Poultry Science Journal, 2022 – Mycoplasma Control Strategies in South Asia.

Indian Animal Health Industry
The veterinary healthcare sector in India is experiencing significant growth, with the market size estimated to be USD 1.25 billion in 2024, projected to reach USD 1.89 billion by 2029, indicating a robust CAGR of 8.63% during the forecast period. This growth is particularly notable in the poultry industry, which has emerged as one of the fastest-growing sectors among livestock species. The poultry sector has evolved into a key supplier of affordable protein sources, driving the development of value chains that cater to consumer demand.

Stallen South Asia: Leading by Change and Setting a Standard
In response to this market dynamic, Stallen South Asia Private Limited has emerged as a key player, offering indigenous solutions and expertise in animal health. By bridging the gap between global standards and local requirements, companies like Stallen are not only contributing to the growth of the poultry industry but also fostering a resilient and sustainable ecosystem for animal health management in the country.

Stallen stands out as a leading name in India’s animal health sector, offering a diverse range of products tailored for poultry and cattle across four distinct divisions. These divisions encompass feed additives, biosecurity solutions, formulations, and vaccines, showcasing Stallen’s comprehensive approach to animal health management.

Strategic Collaborations and Industry Partnerships – 25 Years in the Marking
The company’s journey traces back to its inception in 1997. Since inception, Stallen has constantly developed to stay in line with the industry standard – in 2010 Stallen entered a JV with FATRO from Bologna, Italy. This JV enabled Stallen to import and distribute a wide range of killed and live vaccines, further solidifying its position in the market.

Global Reach and Market Presence
Over the 25 years, Stallen has expanded its footprint and capacities. Today, Stallen’s export operations span more than 50 countries across 6 continents serving as a testament to our product quality and service.
In an attempt to completely self suffienct, Stallen has backward integrated and control the end-to-end supply chain. As a result, they currently operate 5 different manufacturing locations in addition to the 2 supply plants of FATRO:
1) Feed Additives Manufacturing Unit in Palghar, Maharashtra
2) Feed Additives Manufacturing Unit in Sajjanpada, Maharashtra
3) Feed Additives and Cattle Feed Premix Manufacturing Unit in Alexandria, Canada
4) Therapeutics/Formulations Manufacturing Unit in Nandore, Maharashtra
5) Halquinol API Manufacturing Unit in Vatva, Gujarat

Focus on Quality and Regulatory Compliance
All of Stallen’s plants are certified and regularly audited by ISO, GMP, and FDA, along with approvals from international regulatory bodies, attestesting to their adherence to rigorous standards in manufacturing and product safety.

1) Feed Additives and Premix Factories in Maharashtra
Stallen South Asia Pvt. Ltd., based in Nandore, Maharashtra, India, specializes in manufacturing a wide range of feed additives and supplements. Their product portfolio includes antibacterial solutions, treatments targeting mycoplasmal infections, deworming agents, performance enhancers, anthelmintics, mineral supplements, toxin-binding formulations, antidiarrheals, growth promoters, anticoccidials, water sanitation products, fly control solutions, and disinfectants. These products are meticulously crafted and made available in various convenient forms such as tablets, boluses, powders, oral liquid solutions.

1. Manufacturing Process: The factory has specialized equipment and facilities for the manufacturing process. This includes mixing and blending equipment for creating formulations, granulation machinery for solid products, liquid mixing and filling lines for liquids, and packaging lines for various forms of products.
2. Quality Assurance: Quality control measures are integral to the manufacturing process. Raw materials are tested for purity and quality before use. During production, in-process checks are conducted to ensure consistency and adherence to specifications. Finished products undergo rigorous quality testing for efficacy, safety, and compliance with regulatory standards.
3. Regulatory Compliance: The factory operates in compliance with regulatory requirements set by local and international regulatory bodies, with approvals from China, Iran, Australia and more. This includes adherence to Good Manufacturing Practices (GMP) and documentation of processes to ensure product quality and safety.

2) Formulation Unit in Palghar, Maharashtra, India.
It is a crucial facility for manufacturing pharmaceutical products that range between regular therapeutic drugs as well as beta-lactam formulations.
1. Facilities and Equipment: The formulation unit is equipped with state-of-the-art facilities and machinery required for the formulation and production of pharmaceutical products. This includes equipment for mixing, blending, granulation, drying, and packaging. The capacities are built for effervescent tablets, liquid form (oral and topical), oral powder, bolus and ointment.

2. Quality Control: Throughout the formulation process, rigorous quality control measures are implemented to ensure that the final product meets regulatory standards and specifications. This includes testing the raw materials, in-process samples, and the finished product for purity, potency, stability, and safety.

3. Regulatory Compliance: The formulation unit operates in compliance with regulatory requirements set by authorities such as the Food and Drug Administration (FDA) in India. This includes adherence to Good Manufacturing Practices (GMP), documentation of processes, and regular inspections to ensure quality and safety standards are maintained.

3) “Stallen Unveils Cutting-Edge API Facility for Halquinol Production!”
To maintain its commitment to quality, affordability, and timely delivery, Stallen has commenced the production of Halquinol, a non-antibiotic growth promoter classified under hydroxy-quinolines. This compound comprises 5-chloro-8-hydroxyquinoline, 5,7-Dichloro-8-hydroxyquinoline, and 7-Chloro-8-hydroxyquinoline, with the product Halquinol 98% manufactured in accordance with BP 80 (British Pharmacopeia 1980) specifications. Stallen offers Halquinol 98% as a chemical API for use in veterinary formulations and feed additives, alongside the commonly available 60% and 12% variants. With its adherence to BP specifications and increased monthly production capacity, Stallen is well-equipped to cater to global demand, holding valid registrations for Halquinol in over 15 countries.

Stallen’s strategic vision includes gradually introducing a range of APIs from its Vatva facility, aiming to reduce reliance on imported products from China in the animal health sector. The Vatva plant marks the fifth addition to Stallen’s manufacturing infrastructure, complementing its existing feed additive and veterinary formulation facilities in Palghar, Maharashtra, as well as a feed premix and additive manufacturing unit in Canada. This strategic expansion underscores Stallen’s commitment to self-sufficiency and quality assurance in delivering essential solutions for animal health and nutrition.